- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05432479
Study to Evaluate the Efficacy of a Probiotic in Infantile Colic Symptoms Relief (PIXAR)
A Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy of a Probiotic in Infantile Colic Symptoms Relief
This study evaluates the efficacy of single strain probiotic administered in a form of a sachet in the treatment of infant colic in infants 3-12 weeks old.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Maharashtra
-
Pune, Maharashtra, India, Pune 411 041
- Pulse Multispeciality Hospital,
-
-
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Atlantia Food Clinical Trials
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Gestational age of minimum 37 weeks.
- Birthweight of minimum 2500 g (5.5 lb.).
- Age of greater than 3 weeks and less than 12 weeks at enrolment.
- Confirmed Infantile colic defined as: parental report of crying and/or fussing ≥3 hours/day for ≥3 days/week, confirmed prior to enrolment with an infant behaviour diary recording >3 hours of crying in a 24-hour period (eDiary App completed daily during run-in period & for duration of study).
- Participant Informed Consent form signed by parent or legal guardian.
- Infant is considered healthy following physical exam.
- Parents/Caregivers are willing to comply with the trial procedures, and the mother of the infant can attend all three trial visits
Exclusion Criteria:
- Use of antibiotics by the infant within 2-weeks prior to the screening visit or during the run-in period of the trial.
- Use of probiotic supplements from child's birth to enrolment (this includes infant formulas containing probiotics).
- Need for hospitalization (defined as readmission to a hospital ward after initial discharge following delivery).
- Congenital disorders that, in the opinion of the investigator, would impact the gastrointestinal tract.
- Failure to thrive.
- Known lactose or gluten intolerance.
- Known allergy to cow's milk proteins, fish, or any of the substances of the trial product or placebo.
- Known other causes for abdominal pain (e.g., pyloric stenosis).
- Participation in any other interventional clinical study.
- Immuno-compromised participant or participant with other severe chronic disorder.
- Use of probiotic supplements by breastfeeding mother from child's birth to enrolment.
- Use of antibiotics by breastfeeding mother within 2-weeks prior to the screening visit or during the run-in period of the trial.
- Any Participant/Parent/Caregiver who is an employee of the investigational site or an Atlantia Clinical Trials employee or their close family member or a member of their household.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Active
Arm receiving investigation product (probiotic) |
Single strain probiotic in a form of a sachets with a daily dose of 1.0E+9 Colony Forming Unit (CFU) per day for 4 weeks |
|
Placebo Comparator: Placebo
Arm receiving placebo |
Placebo |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in cry and fuss time
Time Frame: Day 0, Day 28
|
eDiary parent reported cry and fuss time |
Day 0, Day 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in cry and fuss time
Time Frame: Day 0, Day 7
|
eDiary parent reported cry and fuss time |
Day 0, Day 7
|
|
Resolution of colic symptoms
Time Frame: Day 0, Day 28
|
Reduction of cry and fuss time (parent reported) greater than 90% comparing to baseline |
Day 0, Day 28
|
|
Change in cry and fuss time bouts
Time Frame: Day 0, Day 7, Day 28
|
eDiary parent reported cry and fuss bouts |
Day 0, Day 7, Day 28
|
|
Change in sleeping time
Time Frame: Day 0, Day 7, Day 28
|
eDiary parent reported sleep time |
Day 0, Day 7, Day 28
|
|
Change in the use of rescue medications
Time Frame: Day 0, Day 28
|
Change in the proportion of participants needing to use rescue medications between the study arms |
Day 0, Day 28
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in maternal quality of life and mental health
Time Frame: Day 0, Day 28
|
Change in maternal QoL using WHO QOL/BREF (improvement marked by increase in the total score) |
Day 0, Day 28
|
|
Change in maternal quality of life and mental health
Time Frame: Day 0, Day 28
|
Change in maternal QoL using MAPP/QoL (improvement marked by increase in the total score) |
Day 0, Day 28
|
|
Resolution of colic symptoms
Time Frame: Day 0, Day 28
|
Reduction of cry and fuss time (parent reported) greater than 50% comparing to baseline |
Day 0, Day 28
|
|
Change in the use of rescue medication drops
Time Frame: Day 0, Day 7, Day 28
|
Change in the number of rescue medication drops used between the study arms |
Day 0, Day 7, Day 28
|
|
Change in duration of daily crying and fussing episodes
Time Frame: Day 0, Day 7, Day 28
|
Change in mean duration per crying and fussing episode per day |
Day 0, Day 7, Day 28
|
|
Changes in gut microbiome composition
Time Frame: Day 0, Day 28
|
Changes in microbiome composition as measured by changes in alpha and beta diversity of the gut microbiome throughout the study as compared to placebo and baseline |
Day 0, Day 28
|
|
Change in fecal calprotectin concentration
Time Frame: Day 0, Day 28
|
Changes in fecal calprotectin concentration throughout the study as compared to placebo and baseline |
Day 0, Day 28
|
|
Adverse Events (AEs)
Time Frame: From enrolment to Day 35
|
Reports of Adverse Events (AEs) and Serious Adverse Events (SAEs) |
From enrolment to Day 35
|
|
Change in vital signs
Time Frame: Day 0, Day 28
|
Changes in vital sign measurements (heart rate [bpm] and body temperature [°F]) collected during the study will be summarised by treatment group |
Day 0, Day 28
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PCTB202010
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.